NCT00002016View on ClinicalTrials.gov

A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Cytomegalovirus RetinitisHIV Infections
Interventions
DRUG

Sevirumab

Trial Locations (2)

77550

Univ TX Galveston Med Branch, Galveston

02114

Harvard (Massachusetts Gen Hosp), Boston

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY

NCT00002016 - A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis | Biotech Hunter | Biotech Hunter